Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab + CRT in Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07836049Phase 2Not yet recruiting
- Sponsor
- Vanderbilt-Ingram Cancer Center
- Start
- Dec 2026
- Primary completion
- Dec 2030
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of toripalimab in Esophageal Squamous Cell Carcinoma (ESCC), sponsored by Vanderbilt-Ingram Cancer Center. Primary endpoint: Clinical Complete Response Rate. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
toripalimab
03
Conditions
Esophageal Squamous Cell Carcinoma (ESCC)
Beyond the preview
Go deeper on NCT07836049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07836049.